CancerRadarCancerRadar
Mis à jour quotidiennement

La recherche sur le cancer, expliquée pour tous

CancerRadar analyse les nouvelles recherches publiées et traduit les découvertes importantes en langage clair.

Parcourir par type de cancer

🎗️Breast Cancer
✦ Découverte significative cette semaine20 nouvelles découvertes cette semaine
🩺Colorectal Cancer
✦ Découverte significative cette semaine4 nouvelles découvertes cette semaine
🩸Leukemia
3 nouvelles découvertes cette semaine
🫁Lung Cancer
✦ Découverte significative cette semaine20 nouvelles découvertes cette semaine
☀️Melanoma
1 nouvelle découverte cette semaine
🎗️Ovarian Cancer
1 nouvelle découverte cette semaine
💜Pancreatic Cancer
2 nouvelles découvertes cette semaine
🧬Prostate Cancer
2 nouvelles découvertes cette semaine

Mode de vie et facteurs de risque

Comment l'alimentation, le poids, le tabagisme et l'environnement sont liés au risque de cancer, fondé sur des recherches évaluées par des pairs.

Parcourir les sujets →

Dispositifs médicaux et procédures

Ablation, radiothérapie, chirurgie robotique: comment ces technologies fonctionnent et ce que dit la recherche.

Parcourir les dispositifs →

Glossaire de recherche

Immunothérapie, biomarqueurs, phases d'essais cliniques: explications en langage clair des termes rencontrés dans les actualités de recherche.

Parcourir le glossaire →

Découvertes récentes

Tout voir →
Étude observationnelleModèles observés dans des populations au fil du temps, pas une expérience contrôlée.Breast CancerPublished: May 18, 2026

Obesity Linked to Poorer Outcomes in Young Women with Certain Breast Cancer

Researchers studied 5,094 premenopausal women with a specific type of breast cancer in China. They found that women who were obese had poorer outcomes compared to those who were underweight, normal weight, or overweight. The study suggests that obesity may be an independent risk factor for breast cancer recurrence in these women.

Why it matters: This finding may help doctors better understand how to treat young women with this type of breast cancer and how to manage their weight to improve their prognosis.
PubMed↗
Essai de phase 1Premier essai chez l'homme. Se concentre sur la sécurité et le dosage dans de petits groupes.Lung CancerPublished: May 18, 2026

Combining Futibatinib and Binimetinib in Advanced Cancer Treatment

Researchers tested a combination of two cancer drugs, futibatinib and binimetinib, in lab experiments and a small clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation →. They found that the combination showed promise in treating certain types of lung cancer, but the trial was stopped due to side effects. The exact effectiveness of this combination is still unclear.

Why it matters: This study contributes to the ongoing search for effective treatments for advanced cancer, particularly for patients with KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-mutant non-small cell lung cancer.

The trial was stopped early due to side effects, and the sample size was small.

PubMed↗
RevueRésumé et analyse des études publiées existantes.Breast CancerPublished: May 18, 2026

Mapping Research on Preventing a Common Side Effect of Breast Cancer ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →

Researchers analyzed a large collection of studies on a type of medication called long-acting G-CSF, which helps prevent a serious side effect of breast cancer chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → called febrile neutropenia. They found that the research on this topic has grown rapidly and is now focusing on how to implement it in real-world practice. The study aimed to provide a clear overview of the current state of research on this topic.

Why it matters: This study may help identify future research priorities and provide a framework for navigating the complex evidence base on febrile neutropenia prevention.

The study analyzed a large collection of studies, but it did not present any new data or results.

PubMed↗
RevueRésumé et analyse des études publiées existantes.Breast CancerPublished: May 18, 2026

Genomic Science and Breast Cancer in Males

Researchers looked at how genomic science can help identify and treat breast cancer in males. They found that individuals with a family history of breast cancer may be at higher risk. This is an area where nurses can play a key role in providing care.

Why it matters: This research highlights the importance of genomic science in understanding and treating breast cancer in males, particularly in those with a family history.
PubMed↗
Étude observationnelleModèles observés dans des populations au fil du temps, pas une expérience contrôlée.Breast CancerPublished: May 18, 2026

Kenyan Study Tests New Approach to Increase Breast and Cervical Cancer Screenings

Researchers in Kenya are testing a new program called C3Link to see if it can increase the number of women getting breast and cervical cancer screenings. The program includes community and clinic strategies to address barriers to screening. The study will compare the C3Link program to usual care.

Why it matters: This study could provide insights into how to improve cancer screening rates in low-resource settings.
PubMed↗
✦ Résultat significatifSignal important issu d'une recherche à un stade avancé, ou résultat solide de phase 2 qui se distingue des résultats habituels.Essai de phase 3Grand essai contrôlé comparant des traitements. Le niveau de preuve d'essai le plus solide.Lung CancerPublished: May 18, 2026

New Insights into Lung Cancer Treatment without Tobacco History

Researchers analyzed data from 741 patients with lung cancer who never smoked and didn't have specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. They found that high levels of certain proteins and immune cells in the tumor were associated with better treatment outcomes. The study suggests that combining different treatments may improve results for these patients.

Why it matters: This finding could help doctors choose the best treatment options for patients with lung cancer who don't smoke and don't have specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
Efficacy

Objective response rate was 23.2%, median progression-free survival was 4.5 months, and median overall survival was 16.8 months.

PubMed↗

Qu'est-ce que CancerRadar?

CancerRadar est un moniteur public de recherche. Il analyse quotidiennement des publications évaluées par des pairs, des registres d'essais cliniques et des sources faisant autorité, puis explique ce qui est nouveau et pourquoi cela pourrait avoir de l'importance, sans exagérer les preuves.

Chaque découverte est liée à sa source originale. Les stades de preuve sont clairement étiquetés: préclinique, phase d'essai, observationnelle ou niveau de revue. Nous ne diagnostiquons pas, ne recommandons pas de traitement et ne donnons pas de conseils médicaux.

Lire notre méthodologie →